drugset / Trial / NCT00678483
Long-Term Effect of 10 mg Versus 20 mg Rimonabant in Overweight or Obese Patients
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The primary objective of this study is to assess, over a period of 12 months, the effect on weight loss and weight maintenance of rimonabant 10 mg in comparison with rimonabant 20 mg in overweight/obese patients after an initial treatment period of 6 months with rimonabant 20 mg. Secondary objectives are to assess the effect of rimonabant over a period of 12 months on waist circumference, high-density lipoprotein (HDL)-Cholesterol and triglycerides (TG), fasting plasma glucose (FPG), fasting insulin and to evaluate the long-term safety and tolerability of rimonabant 10 mg and 20 mg over a period of 12 months after randomization in overweight/obese patients.
Timeline
- Start
- 2008-04
- Primary completion
- 2008-11
- Completion
- 2009-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rimonabant | Small molecule | 10 mg | — |
| Subject | Rimonabant | Small molecule | 20 mg | — |